ARTICLE | Product Development
CVOT damage in diabetes
How FDA’s CVOT guidance has affected diabetes drug development
October 20, 2018 2:10 AM UTC
As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented.
In December 2008, FDA issued guidance requiring diabetes companies to show in pre-market studies that new drug candidates do not increase cardiovascular risk by more than 80%, and to conduct post-market cardiovascular outcomes trials to rule out an increase of ≥30%. The agency began implementing that guidance in 1H09...
BCIQ Company Profiles
BCIQ Target Profiles